Get started
Author

Hisayuki Katsuyama

Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease
2021 · Hidekatsu Yanai, Hiroki Adachi, et al. · International Journal of Molecular Sciences · 654
PDF
Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
2019 · Sabine Kahl, Sofiya Gancheva, et al. · Diabetes Care · 384
Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial
2017 · Kohjiro Ueki, Takayoshi Sasako, et al. · The Lancet Diabetes & Endocrinology · 321
PDF
Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
2023 · Hidekatsu Yanai, Hiroki Adachi, et al. · International Journal of Molecular Sciences · 216
PDF
Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice
2015 · Atsushi Obata, Naoto Kubota, et al. · Endocrinology · 143
Association of handgrip strength with hospitalization, cardiovascular events, and mortality in Japanese patients with type 2 diabetes
2017 · Hidetaka Hamasaki, Yu Kawashima, et al. · Scientific Reports · 111
PDF
An Improvement of Cardiovascular Risk Factors by Omega-3 Polyunsaturated Fatty Acids
2018 · Hidekatsu Yanai, Yoshinori Masui, et al. · Journal of Clinical Medicine Research · 100
PDF
TCF7L2 in mouse pancreatic beta cells plays a crucial role in glucose homeostasis by regulating beta cell mass
2013 · Iseki Takamoto, Naoto Kubota, et al. · Diabetologia · 90
PDF
Effects of Dietary Fat Intake on HDL Metabolism
2014 · Hidekatsu Yanai, Hisayuki Katsuyama, et al. · Journal of Clinical Medicine Research · 71
PDF
Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments
2023 · Hidekatsu Yanai, Hiroki Adachi, et al. · International Journal of Molecular Sciences · 66
PDF
Rimonabant Ameliorates Insulin Resistance via both Adiponectin-dependent and Adiponectin-independent Pathways
2008 · Taku Watanabe, Naoto Kubota, et al. · Journal of Biological Chemistry · 53
The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus
2015 · Misuzu Ueyama, Nao Nishida, et al. · Journal of Gastroenterology · 49
Exercise Therapy for Patients With Type 2 Diabetes: A Narrative Review
2018 · Hidekatsu Yanai, Hiroki Adachi, et al. · Journal of Clinical Medicine Research · 45
PDF
Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk
2022 · Hidekatsu Yanai, Hiroki Adachi, et al. · International Journal of Molecular Sciences · 44
PDF
A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease
2024 · Hidekatsu Yanai, Hiroki Adachi, et al. · Cells · 43
PDF
Daily Physical Activity Assessed by a Triaxial Accelerometer Is Beneficially Associated with Waist Circumference, Serum Triglycerides, and Insulin Resistance in Japanese Patients with Prediabetes or Untreated Early Type 2 Diabetes
2015 · Hidetaka Hamasaki, Mitsuhiko Noda, et al. · Journal of Diabetes Research · 40
PDF
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis
2016 · Hisayuki Katsuyama, Hidetaka Hamasaki, et al. · Journal of Clinical Medicine Research · 39
PDF
Hospitalization with hypoglycemia in patients without diabetes mellitus: A retrospective study using a national inpatient database in Japan, 2008–2012
2017 · Akahito Sako, Hideo Yasunaga, et al. · Medicine · 36
Design of and rationale for the Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): a multicenter, open-label, randomized, parallel-group trial
2016 · Kohjiro Ueki, Takayoshi Sasako, et al. · BMJ Open Diabetes Research & Care · 35
PDF
Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors
2021 · Hidekatsu Yanai, Mariko Hakoshima, et al. · International Journal of Molecular Sciences · 34
PDF
Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications
2023 · Hidekatsu Yanai, Hiroki Adachi, et al. · Biology · 33
PDF
Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline Data
2017 · Hidekatsu Yanai, Mariko Hakoshima, et al. · Journal of Clinical Medicine Research · 31
PDF
Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering
2015 · Hidekatsu Yanai, Hisayuki Katsuyama, et al. · Journal of Clinical Medicine Research · 30
PDF
A Significant Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes
2022 · Hidekatsu Yanai, Mariko Hakoshima, et al. · Cardiology Research · 28
PDF
Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment
2022 · Hidekatsu Yanai, Hiroki Adachi, et al. · International Journal of Molecular Sciences · 27
PDF
Works count: 104
Citation count: 3,210
H-index: 25
I10-index: 45
Year
Topic
Type